Tag: AMyris

New arrival in biobased baby care, but Amyris isn’t only one turning to skin care

New arrival in biobased baby care, but Amyris isn’t only one turning to skin care

September 7, 2019 |

In California,  Amyris has a new baby in town. Babies are booming with about 250 babies born every minute on the planet, and clean and green baby care demand is booming along with it as parents and caregivers are more aware of toxic chemicals and questionable ingredients in cosmetics and skin care. Amyris knows this […]

Read More

Amyris on track to meet plan of $150M revenue for the year

Amyris on track to meet plan of $150M revenue for the year

August 10, 2019 |

In California, Amyris said on a business update call for investors last week that their revenue plan year-to-date is on track to meet their plan of $150 million for the year. Flavors and fragrances are expected to exceed revenue plan for the year and there has been a great market reaction to Purecane with early successful […]

Read More

Amyris executes strategic supply agreements with Raizen

Amyris executes strategic supply agreements with Raizen

May 21, 2019 |

In California, Amyris announced the execution of strategic supply agreements with Raizen for the supply of sugar, energy and other utilities to its new planned production plant co-located with Raizen’s Barra Mill at Barra Bonita, Brazil. In addition to the supply agreements, the companies entered into an arrangement to establish the basis for the creation […]

Read More

Amyris receives first cash payment of $10 million for reaching cannabinoid milestones

Amyris receives first cash payment of $10 million for reaching cannabinoid milestones

May 20, 2019 |

In California, Amyris reported that it has received from its cannabinoid partner, LAVVAN, a first cash payment of $10 million for having successfully delivered on its first major collaboration milestone as announced on March 29, 2019. “We are very pleased with the continued strong execution of our business strategy and the performance of our technology […]

Read More

Amyris Completes Sale of Vitamin E Royalty to DSM

Amyris Completes Sale of Vitamin E Royalty to DSM

April 21, 2019 |

In California, Amyris, Inc. sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility […]

Read More

Learnings from the Earnings – Who’s Up? Who’s Down?

Learnings from the Earnings – Who’s Up? Who’s Down?

March 23, 2019 |

The lucky 13 – with spring comes a sense of renewal and this season these lucky 13 bioeconomy bellwethers recently shared their 2018 and Q4 earnings to reveal uncertainties with trade wars, especially between the U.S. and China, some deals that fell through impacting losses, and pricing issues. But all is not lost as there […]

Read More

Amyris part of major NIH project to bioengineer vaccine adjuvants alternative

Amyris part of major NIH project to bioengineer vaccine adjuvants alternative

February 12, 2019 |

In California, Amyris, Inc. and IDRI (Infectious Disease Research Institute announced IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases (part of the U.S. National Institutes of Health) to discover sustainable alternatives to shark squalene to use as vaccine adjuvants (grant number: R01AI135673). Funding is provided by a […]

Read More

Amyris seals $255 million development and commercialization deal for cannabinoids

Amyris seals $255 million development and commercialization deal for cannabinoids

February 6, 2019 |

In California, Amyris announced that it has signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones […]

Read More

Amyris signs with Chinese company nutritional product royalty arrangement

Amyris signs with Chinese company nutritional product royalty arrangement

December 31, 2018 |

In California, Amyris, Inc. announced that it has signed a long-term agreement with Xinfu of China for a significant initial payment and a long-term minimum annual share of an existing nutritional product royalty arrangement. This agreement enables Amyris to monetize a portion of the long-term royalty opportunity for this product upfront to better manage volatility […]

Read More

Amyris teams with Spanish fermentation company to expand production

Amyris teams with Spanish fermentation company to expand production

December 10, 2018 |

In California, Amyris announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions, through its fermentation division ADL Biopharma. ADL Bionatur, a European leader in research and development of health products, services and industrial fermentation production, provides cost effective, contract manufacturing capabilities. This marks the second expansion of […]

Read More